MedPath

Necitumumab

Generic Name
Necitumumab
Brand Names
Portrazza
Drug Type
Biotech
CAS Number
906805-06-9
Unique Ingredient Identifier
2BT4C47RUI
Background

Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression. Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression of EGFR. Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC).

Indication

Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC.

Associated Conditions
Metastatic Non-Small Cell Lung Cancer
Clinical Trials
Related News

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

First Posted Date
2019-05-10
Last Posted Date
2025-01-30
Lead Sponsor
AstraZeneca
Target Recruit Count
247
Registration Number
NCT03944772
Locations
🇸🇪

Research Site, Stockholm, Sweden

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Phase 1
Terminated
Conditions
Squamous Cell Carcinoma
Interventions
Biological: ETBX-011
Biological: ETBX-021
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-4000
Biological: GI-6207
Biological: GI-6301
Biological: haNK for infusion
Procedure: SBRT
Biological: N-803
First Posted Date
2017-12-29
Last Posted Date
2024-08-05
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
4
Registration Number
NCT03387111
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2
Withdrawn
Conditions
Locally Advanced Squamous Non-Small Cell Lung Cancer
Metastatic Squamous Non-Small Cell Lung Cancer
Interventions
First Posted Date
2016-10-21
Last Posted Date
2019-09-27
Lead Sponsor
Eli Lilly and Company
Registration Number
NCT02941601
Locations
🇬🇧

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom

🇺🇸

Fairview Southdale Oncology Clinic, Edina, Minnesota, United States

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Phase 1
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2016-06-03
Last Posted Date
2024-02-05
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
29
Registration Number
NCT02789345
Locations
🇪🇸

Hospital Universitario Ramon y Cajal, Madrid, Spain

🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei city, Taiwan

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Phase 1
Active, not recruiting
Conditions
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Metastatic Lung Non-Small Cell Carcinoma
Interventions
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Elastography
Procedure: Multigated Acquisition Scan
First Posted Date
2015-07-14
Last Posted Date
2025-04-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
138
Registration Number
NCT02496663
Locations
🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

🇺🇸

Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 12 locations

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

Phase 1
Completed
Conditions
Stage IV Non-Small Cell Lung Cancer
Interventions
First Posted Date
2015-05-22
Last Posted Date
2020-10-05
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
71
Registration Number
NCT02451930
Locations
🇺🇸

Tennessee Oncology PLLC, Nashville, Tennessee, United States

🇯🇵

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sunto-Gun, Japan

🇪🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain

and more 1 locations

A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

Phase 2
Terminated
Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
First Posted Date
2015-05-13
Last Posted Date
2020-12-09
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
31
Registration Number
NCT02443337
Locations
🇺🇸

Southern Cancer Center, P.C., Mobile, Alabama, United States

🇺🇸

Comprehensive Cancer Care and Research Institute of Colorado, Englewood, Colorado, United States

🇺🇸

Chattanooga Oncology Hematology, Chattanooga, Tennessee, United States

and more 10 locations

A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 1
Completed
Conditions
Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Interventions
First Posted Date
2015-04-08
Last Posted Date
2020-07-09
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
66
Registration Number
NCT02411591
Locations
🇪🇸

Hospital Universitario Ramon y Cajal, Madrid, Spain

🇫🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Villejuif, France

🇪🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

Phase 2
Completed
Conditions
Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Interventions
First Posted Date
2015-03-19
Last Posted Date
2020-11-19
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
54
Registration Number
NCT02392507
Locations
🇺🇸

Florida Hospital Cancer Institute, Orlando, Florida, United States

A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer

Phase 2
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2013-02-11
Last Posted Date
2016-06-27
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
61
Registration Number
NCT01788566
Locations
🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy